Abstract
Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID), currently only available as 0.1% ophthalmic suspension (Nevanac®). This study utilized hydroxypropyl-β-cyclodextrin (HPBCD) to increase the water solubility and trans-corneal permeation of nepafenac. The nepafenac-HPBCD complexation in the liquid and solid states were confirmed by phase solubility, differential scanning calorimetry (DSC), X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FT-IR), and nuclear magnetic resonance spectroscopy (NMR) analyses. Nepafenac 0.1% ophthalmic solution was formulated using HPBCD (same pH and osmolality as that of Nevanac®) and pig eye trans-corneal permeation was studied versus Nevanac®. Furthermore, nepafenac content in cornea, sclera, iris, lens, aqueous humor, choroid, ciliary body, retina, and vitreous humor was studied in a continuous isolated pig eye perfusion model in comparison to the suspension and Nevanac®. Permeation studies using porcine corneas revealed that the solution formulation had a permeation rate 18 times higher than Nevanac®. Furthermore, the solution had 11 times higher corneal retention than Nevanac®. Drug distribution studies using porcine eyes revealed that the solution formulation enables detectable levels in various ocular tissues while the drug was undetectable by Nevanac®. The ocular solution formulation had a significantly higher drug concentration in the cornea compared to the suspension or Nevanac®.
Similar content being viewed by others
References
Jones BM, Neville MW. Nepafenac: an ophthalmic nonsteroidal antiinflammatory drug for pain after cataract surgery. Ann Pharmacother. 2013;47(6):892–6.
Gaynes BI, Onyekwuluje A. Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension. Clin Ophthalmol. 2008;2(2):355–68.
Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Topical ocular delivery of NSAIDs. AAPS J. 2008;10(2):229–41.
Walters T, Raizman M, Ernest P, Gayton J, Lehmann R. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2007;33(9):1539–45.
Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: an overview. World J Pharmacol. 2013;2(2):47–64.
Saettone, M.F., Progress and problems in ophthalmic drug delivery, in Future Drug Delivery. 2002, University of Pisa. p. 167–171.
Pharmacy, U.o.N.C.E.S.o. Sterile compounding: ophthalmics. [cited 2015 08/21].
Sieg JW, Robinson JR. Vehicle effects on ocular drug bioavailability i: evaluation of fluorometholone. J Pharm Sci. 1975;64(6):931–6.
Duong HVQ, Westfield KC, Chalkley THF. Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery—prospective randomized double-masked clinical trial. J Cataract Refract Surg. 2007;33(11):1925–9.
Bekers O, Uijtendaal EV, Beijnen JH, Bult A, Underberg WJM. Cyclodextrins in the pharmaceutical field. Drug Dev Ind Pharm. 1991;17(11):1503–49.
Liu L, Guo QX. The driving forces in the inclusion complexation of cyclodextrins. J Incl Phenom Macrocycl Chem. 2002;42(1–2):1–14.
Del Valle EMM. Cyclodextrins and their uses: a review. Process Biochem. 2004;39(9):1033–46.
Sahoo SK, Diinawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today. 2008;13(3–4):144–51.
Loftsson T, Stefansson E. Effect of cyclodextrins on topical drug delivery to the eye. Drug Dev Ind Pharm. 1997;23(5):473–81.
Tiwari G, Tiwari R, Rai AK. Cyclodextrins in delivery systems: applications. J Pharm Bioallied Sci. 2010;2(2):72–9.
Loftsson T, Stefansson E. Cyclodextrins in ocular drug delivery: theoretical basis with dexamethasone as a sample drug. Journal of Drug Delivery Science and Technology. 2007;17(1):3–9.
Uekama K. Design and evaluation of cyclodextrin-based drug formulation. Chem Pharm Bull (Tokyo). 2004;52(8):900–15.
Challa R, Ahuja A, Ali J, Khar RK. Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech. 2005;6(2):E329–57.
Loftssona T, Jarvinen T. Cyclodextrins in ophthalmic drug delivery. Adv Drug Deliv Rev. 1999;36(1):59–79.
Jansen T, Xhonneux B, Mesens J, Borgers M. Beta-cyclodextrins as vehicles in eye-drop formulations: an evaluation of their effecst on rabbit corneal epithelium. Lens Eye Toxic Res. 1990;7(3–4):459–68.
Jonathan C. Javitt, N.B.J., Peter Mcdonnell, Topical compositions for the eye comprising a beta-cyclodextrin derivative and a carbonic anhydrase inhibitor 1994.
Zeng YJ, Yang J, Huang K, Lee ZH, Lee XY. A comparison of biomechanical properties between human and porcine cornea. J Biomech. 2001;34(4):533–7.
Higuchi T, Connors KA. Phase solubility techniques. Adv Anal Chem Instrum. 1965;4:117–212.
Eleamen GRA, da Costa SC, Lima-Neto RG, Neves RP, Rolim LA, Rolim-Neto PJ, et al. Improvement of solubility and antifungal activity of a new aminothiophene derivative by complexation with 2-hydroxypropyl-beta-cyclodextrin. J Braz Chem Soc. 2017;28(1):116–25.
Chen CC, Chang JH, Lee JB, Javier J, Azar DT. Human corneal epithelial cell viability and morphology after dilute alcohol exposure. Invest Ophthalmol Vis Sci. 2002;43(8):2593–602.
Abarca EM, Salmon JH, Gilger BC. Effect of choroidal perfusion on ocular tissue distribution after intravitreal or suprachoroidal injection in an arterially perfused ex vivo pig eye model. J Ocul Pharmacol Ther. 2013;29(8):715–22.
Mains J, Tan LE, Wilson C, Urquhart A. A pharmacokinetic study of a combination of beta adrenoreceptor antagonists—in the isolated perfused ovine eye. Eur J Pharm Biopharm. 2012;80(2):393–401.
Liao Y, Zhang X, Li C, Huang Y, Lei M, Yan M, et al. Inclusion complexes of HP-beta-cyclodextrin with agomelatine: preparation, characterization, mechanism study and in vivo evaluation. Carbohydr Polym. 2016;147:415–25.
Bramhane DM, Kulkarni PA, Martis EA, Pissurlenkar RR, Coutinho EC, Nagarsenker MS. Characterization of pioglitazone cyclodextrin complexes: molecular modeling to in vivo evaluation. J Pharm Bioallied Sci. 2016;8(2):161–9.
Tang P, Li S, Wang L, Yang H, Yan J, Li H. Inclusion complexes of chlorzoxazone with beta- and hydroxypropyl-beta-cyclodextrin: characterization, dissolution, and cytotoxicity. Carbohydr Polym. 2015;131:297–305.
Oprean C, Mioc M, Csanyi E, Ambrus R, Bojin F, Tatu C, et al. Improvement of ursolic and oleanolic acids’ antitumor activity by complexation with hydrophilic cyclodextrins. Biomed Pharmacother. 2016;83:1095–104.
Tang P, Tang B, Wang Q, Xu K, Xiong X, Li H. Effect of hydroxypropyl-beta-cyclodextrin on the bounding of salazosulfapyridine to human serum albumin. Int J Biol Macromol. 2016;92:105–15.
Tang P, Ma X, Wu D, Li S, Xu K, Tang B, et al. Posaconazole/hydroxypropyl-beta-cyclodextrin host-guest system: improving dissolution while maintaining antifungal activity. Carbohydr Polym. 2016;142:16–23.
Alves-Silva I, Sa-Barreto LCL, Lima EM, Cunha-Filho MSS. Preformulation studies of itraconazole associated with benznidazole and pharmaceutical excipients. Thermochim Acta. 2014;575:29–33.
Alonso EC, Riccomini K, Silva LA, Galter D, Lima EM, Durig T, et al. Development of carvedilol-cyclodextrin inclusion complexes using fluid-bed granulation: a novel solid-state complexation alternative with technological advantages. J Pharm Pharmacol. 2016;68(10):1299–309.
Braga MA, Martini MF, Pickholz M, Yokaichiya F, Franco MK, Cabeca LF, et al. Clonidine complexation with hydroxypropyl-beta-cyclodextrin: from physico-chemical characterization to in vivo adjuvant effect in local anesthesia. J Pharm Biomed Anal. 2016;119:27–36.
Zhang CL, Liu JC, Yang WB, Chen DL, Jiao ZG. Experimental and molecular docking investigations on the inclusion mechanism of the complex of phloridzin and hydroxypropyl-beta-cyclodextrin. Food Chem. 2017;215:124–8.
Matencio A, Hernandez-Gil CJ, Garcia-Carmona F, Lopez-Nicolas JM. Physicochemical, thermal and computational study of the encapsulation of rumenic acid by natural and modified cyclodextrins. Food Chem. 2017;216:289–95.
Wei YQ, Zhang J, Zhou Y, Bei WY, Li Y, Yuan QP, et al. Characterization of glabridin/hydroxypropyl-beta-cyclodextrin inclusion complex with robust solubility and enhanced bioactivity. Carbohydr Polym. 2017;159:152–60.
IR Spectroscopy Tutorials: Amines IR Spectroscopy Tutorials [cited 2017; Available from: www.orgchemboulder.com/spectroscopy/irtutor/aminesir.shtml.
Cuming RS, Abarca EM, Duran S, Wooldridge AA, Stewart AJ, Ravis W, Babu RJ, Lin YJ, Hathcock T. Development of a sustained-release voriconazole-containing thermogel for subconjunctival injection in horses. Invest Ophthalmol Vis Sci. 2017;58(5):2746–2754.
Masson M, Loftsson T, Masson G, Stefansson E. Cyclodextrins as permeation enhancers: some theoretical evaluations and in vitro testing. J Control Release. 1999;59(1):107–18.
Tahara K, Karasawa K, Onodera R, Takeuchi H. Feasibility of drug delivery to the eye's posterior segment by topical instillation of PLGA nanoparticles. Asian Journal of Pharmaceutical Sciences. 2017;12(4):394–9.
Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. Aaps Journal. 2010;12(3):348–60.
Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci. 1998;87(12):1479–88.
Acknowledgements
The authors acknowledge Dow Chemical Company and Auburn University Lambert-Powell Meats Laboratory for their generosity.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shelley, H., Grant, M., Smith, F.T. et al. Improved Ocular Delivery of Nepafenac by Cyclodextrin Complexation. AAPS PharmSciTech 19, 2554–2563 (2018). https://doi.org/10.1208/s12249-018-1094-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12249-018-1094-0